Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 1.00 |
| ▸ | LCK | P06239 | 11/20 | 1.00 |
| ▸ | TEK | Q02763 | 10/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | PRKCG | P05129 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | PRKCH | P24723 | 1/20 | 1.00 |
| ▸ | PRKCI | P41743 | 1/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 1/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 1/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 1/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.82 |
| ▸ | ABL1 | P00519 | 3/20 | 0.82 |
| ▸ | ABL2 | P42684 | 2/20 | 0.82 |
| ▸ | FYN | P06241 | 2/20 | 0.76 |
| ▸ | LYN | P07948 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075318 | 0.94 | SRC (0.89) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL24458713 | 0.93 | LCK (0.88) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL24458415 | 0.93 | LCK (0.88) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL24458410 | 0.93 | LCK (0.88) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL8128439 | 0.92 | LCK (0.85) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL8930209 | 0.91 | EGFR (1.00) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL2075814 | 0.88 | LCK (0.83) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL6461712 | 0.88 | SRC (0.80) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL6467833 | 0.87 | SRC (0.82) | SRCLCKTEKKDRPRKD3 | |
| SCHEMBL6465493 | 0.87 | SRC (0.82) | SRCLCKTEKKDRPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1134439-C | Pyrrolo [2,3D ] pyrimidines and their use as tyrosine kinase inhibitors | 艾博特股份有限两合公司 | 2004-01-14 | — | — | CN | claimed |
| EP-0970084-B1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AG (DE) | 2003-06-04 | — | — | EP | claimed |
| CN-1259950-A | Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors | BASF AG (DE) | 2000-07-12 | — | — | CN | claimed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| CN-1134439-C | Pyrrolo [2,3D ] pyrimidines and their use as tyrosine kinase inhibitors | 艾博特股份有限两合公司 | 2004-01-14 | — | — | CN | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-0970084-B1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AG (DE) | 2003-06-04 | — | — | EP | disclosed |
| CN-1335849-A | Pyrrolopyrimidines as protein kinase inhibitors | BASF AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| CN-1259950-A | Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors | BASF AG (DE) | 2000-07-12 | — | — | CN | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0970084-A1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-12 | — | — | EP | disclosed |
| US-6001839-A | Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | disclosed |
| WO-1998041525-A1 | PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | SRC 206/4885LCK 6/4885TEK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.